Introduction：Basic information about 5-Methyl-3,4-diphenylisoxazole CAS 37928-17-9, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
5-Methyl-3,4-diphenylisoxazole Basic information
| Product Name: | 5-Methyl-3,4-diphenylisoxazole |
| Synonyms: | Valdecoxib Impurity 10 (Desulfonamide);4-diphenyl-(Parecoxib sodiuM inteMediate);5-Methyl-3;Parecoxib impurity 5/5-methyl-3,4-diphenylisoxazole;Isoxazole, 5-Methyl-3,4-diphenyl- (Parecoxib sodiuM inteMediate);Isoxazole, 5-Methyl-3,4-diphenyl-;3,4-Diphenyl-5-methylisoxazole;5-Methyl-3,4-diphenylisoxazole |
| CAS: | 37928-17-9 |
| MF: | C16H13NO |
| MW: | 235.28 |
| EINECS: | 1592732-453-0 |
| Product Categories: | API;1 |
| Mol File: | 37928-17-9.mol |
|
5-Methyl-3,4-diphenylisoxazole Chemical Properties
| Melting point | 96.0 to 100.0 °C |
| Boiling point | 340.1±21.0 °C(Predicted) |
| density | 1.108±0.06 g/cm3(Predicted) |
| storage temp. | Sealed in dry,Room Temperature |
| solubility | Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) |
| form | Solid |
| pka | -2.53±0.50(Predicted) |
| color | White to Off-White |
| InChI | InChI=1S/C16H13NO/c1-12-15(13-8-4-2-5-9-13)16(17-18-12)14-10-6-3-7-11-14/h2-11H,1H3 |
| InChIKey | ZXIRUKJWLADSJS-UHFFFAOYSA-N |
| SMILES | O1C(C)=C(C2=CC=CC=C2)C(C2=CC=CC=C2)=N1 |
Safety Information
5-Methyl-3,4-diphenylisoxazole Usage And Synthesis
| Uses | 5-Methyl-3,4-diphenylisoxazole is synthesis The key intermediate of Parecoxib Sodium (Parecoxib Sodium).Parecoxib Sodium is by the Pfizer of the U.S. The cox 2 inhibitor of company's research and development, listed in European Union in 2002, trade name Dynastat, is used for The short term therapy of postoperative pain. |
| Uses | 5-Methyl-3,4-diphenylisoxazole is a reagent for the preparation of valdecoxib and valdecoxib analogues. |
| Synthesis |
In four mouthfuls of round-bottomed flasks of a 1L add compound 2 (40g), methanol (400mL), 7.7% Aqueous sodium carbonate (400mL), is heated to 70°C, after stirring reaction 2h, and TLC plate monitoring raw material Fundamental reaction is complete, and solution is divided into solid-liquid biphase, is extracted with ethyl acetate, collected organic layer, with anhydrous Sodium sulfate is dried, and vacuum obtains white solid, HPLC purity: 94.9% after being spin-dried for.White solid uses 40ml ethyl acetate and the mixed solvent recrystallization of 120ml normal hexane (1:3) again, Obtaining target compound is white solid 34.2g, yield 92%, HPLC purity: 99.7%.m.p.97-98??￡? MS(m/z):236(M+H)+￡?1H NMR(400MHz,CDCl3) |?:2.43(s,3H,-CH3), 7.19-7.43 (m, 10H ,-CH=). |
| References | [1] Patent: CN105949141, 2016, A. Location in patent: Paragraph 0016; 0021; 0022; 0023; 0025; 0027; 0029-0041
[2] Patent: CN104193694, 2016, B. Location in patent: Paragraph 0029; 0030; 0031 |
5-Methyl-3,4-diphenylisoxazole Preparation Products And Raw materials
| Raw materials | 4-IODO-5-METHYL-3-PHENYLISOXAZOLE-->1,3-Butanedione, 1,2-diphenyl--->Isoxazole, 4,5-dihydro-5-methyl-3,4-diphenyl-5-(1-pyrrolidinyl)--->1-PHENYL-1-PROPYNE-->Deoxybenzoin Oxime-->BENZONITRILE OXIDE-->5-METHYL-3,4-DIPHENYL-4,5-DIHYDROISOXAZOL-5-OL-->Pyrrolidine, 1-(1-methyl-2-phenylethenyl)--->Acetic acid-->Benzaldoxime |
| Preparation Products | Parecoxib-->Valdecoxib-->Valdecoxib IMpurity B |
